Around 650 E3 ubiquitin ligases each recognize a specific set of substrates and are potentially attractive therapeutic targets, but they often lack a confined active-site pocket amenable to small ...

Here, we expand the repertoire of PROTAC compatible E3 ligases by identifying a novel small molecule scaffold targeting the ubiquitin E3 ligase KLHDC2 using a fluorescence polarization-based high ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid ...

Scientists have developed a powerful new method for selectively and reversibly breaking connections between brain cells—a ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with rising incidence linked to ...

Shenzhen Zhongge Biotechnology Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agent coupled to interleukin-1 receptor-associated ...

As a SUMO E3 ligase, RANBP2 plays a pivotal role in post-translational modification, specifically SUMOylation, which is essential for regulating the cell cycle. Recent insights have highlighted ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies. As a SUMO ...

Depending on the PTD–E3 ligase pairs, PROTAR influenza viruses show varying levels of attenuation in vitro. In animal models, PROTAR vaccine candidates exhibit significant attenuated ...